When evaluating potential risk factors associated with failure to achieve neoadjuvant therapy goals, our data suggest a potential correlation with non-KIT exon 11 mutations, especially wild-type KIT/PDGFRA GIST, and GIST localization in the small intestine. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.